Search - tctmd.com

Displaying 341 - 360 of 502

Sort: Relevancy | Date

News Daily News

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

December 23, 2015

News Daily News

三联疗法特别是普拉格雷会增加急性心梗患者的出血风险

Yael L. Maxwell

December 22, 2015

News Daily News

Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI

Yael L. Maxwell

December 22, 2015

News Daily News

El Tratamiento Triple, sobre todo con Prasugrel, Aumenta el Riesgo Hemorrágico de los IAM

Yael L. Maxwell

December 22, 2015

News Daily News

早期数据显示抗血小板药物 PZ-128 效果可逆、起效快速，颇具前景

Caitlin E. Cox

December 20, 2015

News Daily News

Prometedores Primeros Datos para el Fármaco Antiplaquetario Reversible de Acción Rápida PZ-128

Caitlin E. Cox

December 20, 2015

News Daily News

Early Data Show Promise for Reversible, Fast-Acting, Antiplatelet Drug PZ-128

Caitlin E. Cox

December 20, 2015

News Daily News

一项观察性研究表明，患者在急性心肌梗死后服用PUFA可真正受益

November 30, 2015

News Daily News

Un Estudio Observacional Revela los Beneficios Reales de Pacientes a Tratamiento con AGPI Post-IAM

November 30, 2015

News Daily News

Observational Study Hints at Real Benefits for Patients Who Take PUFAs After Acute MI

November 30, 2015

News Conference News AHA 2015

Most Drug Discontinuations in PEGASUS-TIMI 54 Related to Dyspnea, Bleeding

Todd Neale

November 10, 2015

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

News Daily News

RECLOSE-3: Shifting Clopidogrel Nonresponders to Prasugrel Lowers Mortality After PCI

Yael L. Maxwell

September 18, 2015

News Industry News

Medicure Announces Filing of sNDA for New AGGRASTAT® Indication

September 10, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Industry News

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

September 09, 2015

News Industry News

New Haven Pharmaceuticals Receives FDA Approval for DURLAZA™ (aspirin) Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events

September 08, 2015

News Industry News

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

September 03, 2015

News Conference News ESC 2015

EXAMINATION: STEMI Patients Fare Better at 5 Years With EES vs BMS

Caitlin E. Cox

September 02, 2015

Advertisement

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

三联疗法特别是普拉格雷会增加急性心梗患者的出血风险

Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI

El Tratamiento Triple, sobre todo con Prasugrel, Aumenta el Riesgo Hemorrágico de los IAM

早期数据显示抗血小板药物 PZ-128 效果可逆、起效快速，颇具前景

Prometedores Primeros Datos para el Fármaco Antiplaquetario Reversible de Acción Rápida PZ-128

Early Data Show Promise for Reversible, Fast-Acting, Antiplatelet Drug PZ-128

一项观察性研究表明，患者在急性心肌梗死后服用PUFA可真正受益

Un Estudio Observacional Revela los Beneficios Reales de Pacientes a Tratamiento con AGPI Post-IAM

Observational Study Hints at Real Benefits for Patients Who Take PUFAs After Acute MI

Most Drug Discontinuations in PEGASUS-TIMI 54 Related to Dyspnea, Bleeding

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Discussion Highlights Merits, Limitations of Small Trials

RECLOSE-3: Shifting Clopidogrel Nonresponders to Prasugrel Lowers Mortality After PCI

Medicure Announces Filing of sNDA for New AGGRASTAT® Indication

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

New Haven Pharmaceuticals Receives FDA Approval for DURLAZA™ (aspirin) Extended Release Capsules for Secondary Prevention of Stroke and Acute Cardiac Events

US FDA Approves Expanded Indication For Brilinta To Include Long-term Use In Patients With a History of Heart Attack

EXAMINATION: STEMI Patients Fare Better at 5 Years With EES vs BMS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content